Millennium Gobbles Up Predictive Medicine, Eyes Pharmacogenomics Future

Mar 09, 2000

Premium

C

AMBRIDGE, Mass.--Millennium Pharmaceuticals announced that it will acquire the remaining shares of its Millennium Predictive Medicine subsidiary that it does not already own, making it a wholly owned subsidiary. The company said that the transaction, a stock-for-stock exchange, will align more closely Millennium’s therapeutic and predictive medicine discovery and development efforts.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Main menu